JAK“新秀”乌帕替尼治疗活动性强直性脊柱炎

Upatinib was developed by Abbvie Company. It is a new Janus kinase (JAK) inhibitor with the trade name Rinvoq. It was approved by the U.S. Food and Drug Administration (FDA) on August 16, 2019, and approved by the European Medicines Agency (EMA) on December 16, 2019. Compared with the marketed drugs baricitinib and tofacitinib, it is more selective for JAK1 and has demonstrated good efficacy in patients with rheumatoid arthritis. It can be used alone or in combination with traditional synthetic disease-modifying antirheumatic drugs (csDMARDs) for the treatment of moderate to severe rheumatoid arthritis in adults who have insufficient response to or are intolerant to methotrexate. But a recent study showed that JAK’s “rookie” upadatinib is also very effective in treating active ankylosing spondylitis.

The SELECT-AXIS 1 study is a multi-center, randomized, double-blind, placebo-controlled, parallel-group design Phase II/III clinical study. Previously, the results of Phase 1 of the study had reached the primary endpoint (14-week ASAS40 response rate), confirming the efficacy and safety of upadatinib in the treatment of active ankylosing spondylitis (AS) with poor response to NSAIDs. The results of the study showed that the sustained efficacy of uppatinib in the treatment of AS patients lasted for more than 1 year, and the efficacy of patients who were switched from the placebo group to uppatinib treatment at 14 weeks was equivalent to that of the uppatinib continued treatment group. In terms of safety, no new safety issues were found with upadatinib treatment.

In the study, the symptoms were: upper respiratory tract infection, nausea, cough, and fever. If you are currently using Upatinib, the editor here recommends that patients must take the medication correctly in accordance with the doctor's instructions. Some patients always think that the effect of the drug itself can be improved by increasing the dose of the drug, and they also think that the occurrence of side effects can be reduced by reducing the dose of the drug. However, this is not actually the case. If the dose of the drug is changed privately, it may cause more adverse reactions, so do not use the drug blindly.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.